16 closest matches · ranked by relevance
Erythema Chronicum Migrans
Primary: Objective Sequelae and Post-treatment Subjective New or Increased Symptoms (NOIS)in Patients Treated for Erythema Migrans With Doxycycline for 10 or 15 Days. — 79; 85…
Erythema Migrans · Post-Lyme Disease Symptoms
Primary: Objective Lyme Disease Manifestations and Post-Lyme Disease Symptoms at 14 Days — 30; 27 participants
Erythema Multiforme
Primary: Erythema Multiforme Flares on Medication — 1.7 Number of flares
Erythema Migrans
Primary: Detection of Borrelia Burgdorferi Sensu Lato by Microscopy in Dark Field (Positive vs. Negative) — 102; 59 culture-positive skin samples
Lyme Disease
Primary: Detection of Borrelia Burgdorferi in Ticks After Xenodiagnosis Procedure — 1; 0; 418; 319 Ticks
Erythema · Rosacea
Primary: Inter-rater Reliability of the Clinician Erythema Assessment (CEA) Scale — 0.908 Kendall's W
Rosacea
Primary: Pre-Treatment Clinician Erythema Assessment (CEA) — 0; 0; 7; 144 Participants
Migraine
Primary: Migraine Headache Days — 7.12; 6.92; 5.53; 4.79 Days
Platelet Aggregation, Spontaneous · Migraine With Aura · Patent Foramen Ovale
Primary: Change in Migraine Characteristics — 43; 2; 17 Participants
Primary Erythromelalgia · Inherited Erythromelalgia
Primary: Average Daily Use of Cooling for Erythromelalgia-Related Pain in Treatment Period 2 — 0.24; 2.4 cooling uses/day
Skin Rash
Primary: Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and…
Post-Treatment Lyme Disease Syndrome
Primary: Horowitz Lyme-Multiple Systemic Infectious Disease Syndrome Questionnaire — 50.5; 44.8; 33.8; 25.6 score on a scale — p=0.07
Rosacea · Erythema
Primary: Responder — 16.7 percentage of responders
Rosacea · Papulopustular Rosacea
Primary: Improvement of the Inflammatory Lesions (Papules, Pustules, Nodules), Erythema, and Telangiectasia of Rosacea as Assessed by the Investigator's Global Assessment (IGA)…
Rosacea · Erythema
Primary: Percentage of Participants With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Self-Assessment (SSA) — 13.3; 20.5…
Rosacea
Primary: Primary: Percentage of Treatment Success on Day 7 — 9.95; 10.36; 0 percentage of participants — p=<0.0001